Perspective Therapeutics, Inc. - 8-K Filing
Perspective Therapeutics reported $271 million in cash as of March 31, 2026, up from $145 million at year-end 2025, following a February 2026 underwritten offering that raised approximately $164 million. The company incurred a Q1 net loss of $26.2 million ($0.25/share), with R&D expenses rising to $21.4 million (+50% YoY) due to expanded clinical trials and headcount, while G&A costs fell slightly to $7.0 million (-10%). The cash runway is expected through late 2027. (Items: 2.02 Results of Operations and Financial Condition, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $CATX